Status:
COMPLETED
The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs
Lead Sponsor:
Ramathibodi Hospital
Conditions:
Tuberculosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Hepatitis is one of the most common adverse effect from anti-tuberculosis. Silymarin showed its efficacy to decreased serum alanine transaminase enzyme in animal models from recent study. No confirmed...
Detailed Description
\- Prevention of antituberculosis-related drug induced liver injury with silymarin is investigated.
Eligibility Criteria
Inclusion
- tuberculosis cases
- treated with isoniazid, rifampicin, ethambutol and pyrazinamide
Exclusion
- no known liver disease (HBV, HCV), and HIV infection
- normal ALT level before enrollment
- refuse to participate
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2013
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01800487
Start Date
January 1 2012
End Date
July 1 2013
Last Update
December 24 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology and Hepatology, Ramathibodi hospital
Bangkok, Bangkok, Thailand, 10400